Aptevo Therapeutics Operating Income Over Time
| APVO Stock | USD 6.73 0.07 1.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aptevo Therapeutics Performance and Aptevo Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Aptevo diversify its offerings? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptevo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aptevo Therapeutics requires distinguishing between market price and book value, where the latter reflects Aptevo's accounting equity. The concept of intrinsic value - what Aptevo Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aptevo Therapeutics' price substantially above or below its fundamental value.
Understanding that Aptevo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptevo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aptevo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Aptevo Therapeutics and related stocks such as Kiora Pharmaceuticals, ESSA Pharma, and HCW Biologics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KPRX | (5.9 M) | (5.9 M) | (5.9 M) | (3.1 M) | (2.5 M) | (6.7 M) | (13.3 M) | (14.6 M) | (10.8 M) | (7 M) | (6.9 M) | (14.2 M) | (12.3 M) | (12.6 M) | 4.5 M | 4.1 M | 4.3 M |
| HCWB | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (5.8 M) | (13.4 M) | (15.1 M) | (25.7 M) | (29.5 M) | (26.5 M) | (25.2 M) |
| ABP | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | (12.4 M) | (15 M) | (15 M) | (15 M) | (15 M) | (16.7 M) | (11.7 M) | (9.9 M) | (8.9 M) | (9.4 M) |
| MTNB | (116.1 K) | (116.1 K) | (116.1 K) | (3.7 M) | (10.5 M) | (9.9 M) | (8.3 M) | (16.5 M) | (14.6 M) | (18.9 M) | (24.2 M) | (24.7 M) | (24.6 M) | (23.8 M) | (24.6 M) | (22.1 M) | (23.2 M) |
| INAB | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (5.1 M) | (8.6 M) | (14.7 M) | (28.5 M) | (30.3 M) | (30.4 M) | (27.4 M) | (26 M) |
| BCDA | 206.2 K | (618 K) | (339 K) | 9 K | 231 K | 319 K | (7.6 M) | (12.4 M) | (14.1 M) | (14.2 M) | (15.5 M) | (12.6 M) | (11.9 M) | (11.6 M) | (8 M) | (7.2 M) | (6.8 M) |
| CERO | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (332 K) | (2.9 M) | (2.9 M) | (15.3 M) | (13.8 M) | (13.1 M) |
| ERNA | (1.4 M) | (3.3 M) | (1.1 M) | (1.1 M) | (4.7 M) | (6.6 M) | (2.3 M) | (1.4 M) | 464 K | (1.2 M) | (7.2 M) | (113.7 M) | (33.2 M) | (21.1 M) | (15.7 M) | (14.1 M) | (14.8 M) |
Aptevo Therapeutics and related stocks such as Kiora Pharmaceuticals, ESSA Pharma, and HCW Biologics Operating Income description
Operating Income is the amount of profit realized from Aptevo Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Aptevo Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Aptevo Therapeutics | APVO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2401 4th Avenue, |
| Exchange | NASDAQ Exchange |
USD 6.73
Check out Aptevo Therapeutics Performance and Aptevo Therapeutics Correlation. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Aptevo Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.